Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (FMT v/s Microbiome Drugs), By Application (C. Difficile, Crohn’s Disease, Inflammatory Bowel Disease, Diabetes, Others), By Region & Competition, 2021-2031F

January 2026 | 183 pages | ID: M4EF235DA531EN
TechSci Research

Abstracts

The Global Microbiome Therapeutics Market will grow from USD 197.11 Million in 2025 to USD 1013.18 Million by 2031 at a 31.37% CAGR. Microbiome therapeutics are a class of biological drugs designed to manipulate the human microbiome, comprising communities of bacteria, fungi, and viruses, to treat or prevent disease by restoring microbial balance.

Key Market Drivers

Increasing regulatory approvals and favorable guidelines for live biotherapeutic products act as a primary catalyst, transitioning the market from experimental research to commercial viability. The successful authorization of novel therapies validates the underlying science of microbiome restoration, encouraging developer confidence and clinical adoption. This shift is evident in the tangible revenue streams now generated by recently approved assets, which underscores the growing market uptake of these treatments.

Key Market Challenges

The complex regulatory landscape stands as a formidable barrier hampering the growth of the Global Microbiome Therapeutics Market. Unlike traditional small-molecule drugs, microbiome therapeutics consist of living, heterogeneous biological mixtures that present unique difficulties regarding manufacturing consistency, stability, and potency verification. The absence of standardized global guidelines for characterizing these live biotherapeutic products creates significant ambiguity for developers, who must navigate undefined pathways for clinical trial design and safety evaluation. This uncertainty directly stifles market expansion by inflating research costs and extending development timelines, making it difficult for companies to secure the necessary capital for late-stage commercialization.

Key Market Trends

The Integration of Microbiome Therapeutics as Immuno-Oncology Adjuvants is rapidly gaining traction as a pivotal trend, driven by the ability of specific microbial strains to modulate the host immune system and overcome resistance to checkpoint inhibitors. Developers are increasingly focusing on synergistic combinations where live biotherapeutic products prime the tumor microenvironment, thereby enhancing the efficacy of existing cancer immunotherapies like PD-1/PD-L1 blockers. This approach is moving beyond early-stage concepts into robust clinical validation, targeting difficult-to-treat solid tumors.

Key Market Players

• 4D Pharma plc
• Enterome SA
• Finch Therapeutics Group, Inc.
• Vedanta Bioscience, Inc.
• Seres Therapeutics, Inc.
• Microbiotica Limited
• Destiny Pharma plc
• Taisho Pharmaceutical Holdings Co., Ltd.
• AOBiome Therapeutics, Inc.
• Ferring Pharmaceuticals SA

Report Scope:

In this report, the Global Microbiome Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Microbiome Therapeutics Market, By Type:
• FMT v/s Microbiome Drugs
• Microbiome Therapeutics Market, By Application:
• C. Difficile
• Crohn’s Disease
• Inflammatory Bowel Disease
• Diabetes
• Others
• Microbiome Therapeutics Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Microbiome Therapeutics Market.

Available Customizations:

Global Microbiome Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL MICROBIOME THERAPEUTICS MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Type (FMT v/s Microbiome Drugs)
  5.2.2. By Application (C. Difficile, Crohn’s Disease, Inflammatory Bowel Disease, Diabetes, Others)
  5.2.3. By Region
  5.2.4. By Company (2025)
5.3. Market Map

6. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Type
  6.2.2. By Application
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Microbiome Therapeutics Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Type
      6.3.1.2.2. By Application
  6.3.2. Canada Microbiome Therapeutics Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Type
      6.3.2.2.2. By Application
  6.3.3. Mexico Microbiome Therapeutics Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Type
      6.3.3.2.2. By Application

7. EUROPE MICROBIOME THERAPEUTICS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Type
  7.2.2. By Application
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Microbiome Therapeutics Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Type
      7.3.1.2.2. By Application
  7.3.2. France Microbiome Therapeutics Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Type
      7.3.2.2.2. By Application
  7.3.3. United Kingdom Microbiome Therapeutics Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Type
      7.3.3.2.2. By Application
  7.3.4. Italy Microbiome Therapeutics Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Type
      7.3.4.2.2. By Application
  7.3.5. Spain Microbiome Therapeutics Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Type
      7.3.5.2.2. By Application

8. ASIA PACIFIC MICROBIOME THERAPEUTICS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Type
  8.2.2. By Application
  8.2.3. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Microbiome Therapeutics Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Type
      8.3.1.2.2. By Application
  8.3.2. India Microbiome Therapeutics Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Type
      8.3.2.2.2. By Application
  8.3.3. Japan Microbiome Therapeutics Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Type
      8.3.3.2.2. By Application
  8.3.4. South Korea Microbiome Therapeutics Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Type
      8.3.4.2.2. By Application
  8.3.5. Australia Microbiome Therapeutics Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Type
      8.3.5.2.2. By Application

9. MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Type
  9.2.2. By Application
  9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Microbiome Therapeutics Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Type
      9.3.1.2.2. By Application
  9.3.2. UAE Microbiome Therapeutics Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Type
      9.3.2.2.2. By Application
  9.3.3. South Africa Microbiome Therapeutics Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Type
      9.3.3.2.2. By Application

10. SOUTH AMERICA MICROBIOME THERAPEUTICS MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Type
  10.2.2. By Application
  10.2.3. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Microbiome Therapeutics Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Type
      10.3.1.2.2. By Application
  10.3.2. Colombia Microbiome Therapeutics Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Type
      10.3.2.2.2. By Application
  10.3.3. Argentina Microbiome Therapeutics Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Type
      10.3.3.2.2. By Application

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL MICROBIOME THERAPEUTICS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. 4D Pharma plc
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Enterome SA
15.3. Finch Therapeutics Group, Inc.
15.4. Vedanta Bioscience, Inc.
15.5. Seres Therapeutics, Inc.
15.6. Microbiotica Limited
15.7. Destiny Pharma plc
15.8. Taisho Pharmaceutical Holdings Co., Ltd.
15.9. AOBiome Therapeutics, Inc.
15.10. Ferring Pharmaceuticals SA

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER